Adenosine Kinase Expression in the Frontal Cortex in Schizophrenia.
Adenosine
/ metabolism
Adenosine Kinase
/ drug effects
Adult
Aged
Aged, 80 and over
Animals
Antipsychotic Agents
/ pharmacology
Female
Gene Expression
/ drug effects
Gyrus Cinguli
/ drug effects
Hep G2 Cells
Humans
Male
Middle Aged
Prefrontal Cortex
/ drug effects
Rats
Rats, Sprague-Dawley
Schizophrenia
/ drug therapy
Tissue Banks
ACC
DLPFC
neuropsychiatric
postmortem
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
10 04 2020
10 04 2020
Historique:
entrez:
11
4
2020
pubmed:
11
4
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
The adenosine hypothesis of schizophrenia posits that reduced availability of the neuromodulator adenosine contributes to dysregulation of dopamine and glutamate transmission and the symptoms associated with schizophrenia. It has been proposed that increased expression of the enzyme adenosine kinase (ADK) may drive hypofunction of the adenosine system. While animal models of ADK overexpression support such a role for altered ADK, the expression of ADK in schizophrenia has yet to be examined. In this study, we assayed ADK gene and protein expression in frontocortical tissue from schizophrenia subjects. In the dorsolateral prefrontal cortex (DLPFC), ADK-long and -short splice variant expression was not significantly altered in schizophrenia compared to controls. There was also no significant difference in ADK splice variant expression in the frontal cortex of rats treated chronically with haloperidol-decanoate, in a study to identify the effect of antipsychotics on ADK gene expression. ADK protein expression was not significantly altered in the DLPFC or anterior cingulate cortex (ACC). There was no significant effect of antipsychotic medication on ADK protein expression in the DLPFC or ACC. Overall, our results suggest that increased ADK expression does not contribute to hypofunction of the adenosine system in schizophrenia and that alternative mechanisms are involved in dysregulation of this system in schizophrenia.
Identifiants
pubmed: 32275755
pii: 5571187
doi: 10.1093/schbul/sbz086
pmc: PMC7147579
doi:
Substances chimiques
Antipsychotic Agents
0
Adenosine Kinase
EC 2.7.1.20
Adenosine
K72T3FS567
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
690-698Subventions
Organisme : NIMH NIH HHS
ID : R01 MH083973
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH094445
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Purinergic Signal. 2013 Dec;9(4):599-608
pubmed: 23771238
PLoS Med. 2005 May;2(5):e151; quiz e175
pubmed: 15916460
Eur J Neurosci. 2007 Dec;26(11):3237-52
pubmed: 18005073
J Clin Psychiatry. 2005 Feb;66(2):213-9
pubmed: 15705007
BMC Genomics. 2006 Apr 04;7:70
pubmed: 16594998
Mol Psychiatry. 2017 Mar;22(3):430-440
pubmed: 27240532
Mol Psychiatry. 2016 Jun;21(6):823-30
pubmed: 26416546
Schizophr Res. 2007 Jul;93(1-3):409
pubmed: 17389149
J Inherit Metab Dis. 2016 Mar;39(2):273-83
pubmed: 26642971
Neuropsychopharmacology. 2010 Jan;35(2):473-82
pubmed: 19829293
Neuropharmacology. 2018 Oct;141:89-97
pubmed: 30145320
Biochem Biophys Res Commun. 1997 Feb 24;231(3):645-50
pubmed: 9070863
BMC Biochem. 2011 May 17;12:22
pubmed: 21586167
Neuropsychopharmacology. 2018 Jul;43(8):1667-1674
pubmed: 29483661
J Neurosci. 2004 Jan 21;24(3):692-701
pubmed: 14736855
Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84
pubmed: 16773445
Transl Psychiatry. 2014 Feb 25;4:e365
pubmed: 24569695
Psychiatr Genet. 2009 Dec;19(6):328-35
pubmed: 19820430
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jun;30(4):617-29
pubmed: 16580767
Mol Neurobiol. 2019 Jun;56(6):4492-4517
pubmed: 30338483
Schizophr Res. 2013 Jun;147(1):32-38
pubmed: 23566497
J Clin Invest. 2012 Jul;122(7):2567-77
pubmed: 22706302
Science. 2018 Feb 9;359(6376):693-697
pubmed: 29439242
Neuroscience. 2006 Sep 29;142(1):125-37
pubmed: 16859834
Proc Natl Acad Sci U S A. 1983 May;80(10):2829-33
pubmed: 6304684
Med Hypotheses. 2000 Feb;54(2):157-66
pubmed: 10790742
Cell Mol Life Sci. 2008 Sep;65(18):2875-96
pubmed: 18560757
Am J Psychiatry. 2001 Sep;158(9):1367-77
pubmed: 11532718
Brain Res. 1998 Oct 19;808(2):320-3
pubmed: 9767181
Front Mol Neurosci. 2016 Oct 20;9:99
pubmed: 27812320
Biol Psychiatry. 2015 Dec 1;78(11):763-74
pubmed: 25869810
Am J Hum Genet. 2011 Oct 7;89(4):507-15
pubmed: 21963049
Neuropharmacology. 2012 Mar;62(3):1527-43
pubmed: 21315743
Biol Psychiatry. 2018 May 1;83(9):739-750
pubmed: 29217297
Yakubutsu Seishin Kodo. 1986 Jun;6(2):275-80
pubmed: 3022499
J Clin Psychiatry. 2005 Sep;66(9):1122-9
pubmed: 16187769
Biochem Biophys Res Commun. 2009 Oct 9;388(1):46-50
pubmed: 19635462
Anal Biochem. 1985 Oct;150(1):76-85
pubmed: 3843705
Int J Neuropsychopharmacol. 2018 May 1;21(5):405-409
pubmed: 29126171
Braz J Psychiatry. 2010 Sep;32(3):275-8
pubmed: 20414589
Annu Rev Neurosci. 2002;25:409-32
pubmed: 12052915
Epilepsia. 2011 Sep;52(9):1645-55
pubmed: 21635241
J Clin Pharm Ther. 2000 Apr;25(2):131-7
pubmed: 10849191
Schizophr Res. 2000 Aug 3;44(2):151-5
pubmed: 10913747
Int Rev Neurobiol. 2014;119:395-449
pubmed: 25175974
Adv Myocardiol. 1985;6:273-84
pubmed: 2986260